News & Press

Press Releases

Addressing patient needs through scientific driven innovation

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

Press Releases
Preliminary Phase Ib results of ABSK021 for advanced TGCT will be published at the 2022 CTOS annual meeting
Nov 15, 2022
Abbisko Therapeutics completed the first patient enrollment in the Phase II clinical trial for ABSK091 in combination with BeiGene’s Tislelizumab in urothelial carcinoma
Nov 04, 2022
Abbisko Therapeutic announces the clinical trial approval granted by U.S. FDA for its next-generation FGFR inhibitor ABSK121
Nov 01, 2022
Abbisko Therapeutics obtained pivotal Phase III clinical trial approval for CSF-1R inhibitor ABSK021 from the CDE of NMPA
Oct 25, 2022
Abbisko Therapeutics Completed Dosing of First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043
Sep 27, 2022
Abbisko Therapeutics won the 2022 "Future Star" Award of the biopharmaceutical industry
Aug 15, 2022
Abbisko Therapeutics announces China NMPA breakthrough therapy designation granted for its CSF-1R inhibitor ABSK021
Jul 20, 2022
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
Jul 04, 2022
Abbisko Therapeutics Announces the Appointment of Dr. Zidong Zhang as CFO
May 16, 2022
Abbisko Therapeutics Declared Two Next-Generation Precision Oncology Preclinical Candidates and Will Present Multiple Discovery and Translational Research Results at AACR Annual Meeting 2022
Mar 11, 2022
Abbisko Therapeutics Has Obtained IND Approval for ABSK061, an Innovative and Highly Selective FGFR2/3 Inhibitor, from the NMPA
Mar 03, 2022
Abbisko Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate ABSK091 in Combination with Tislelizumab
Feb 15, 2022
Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody
Feb 08, 2022
View all
we discover and develop first-in-class and best-in-class therapies
to address critical unmet needs for cancer patients in China and globally
Media
Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA
Dec 14, 2020
Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome
Jun 19, 2020
Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011
Apr 07, 2020
Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547
Nov 08, 2019
View all

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1